Platinum-based chemotherapy maintenance regimens are often limited by toxicities, highlighting a need for chemotherapy-free strategies that retain efficacy. Previous studies have demonstrated the success of PARP inhibitors (PARPi) in maintenance therapy, even in patients negative for germline BRCA mutations. Additional work illustrating a PARPi-mediated upregulation of immune checkpoint molecules and enhanced immune response suggests a potential for synergism between PARPi and immune checkpoint inhibitors (ICI). In the phase II DORA study, Tan and colleagues investigate the use of the PARPi olaparib with or without the PD-L1-targeted ICI durvalumab in patients with advanced triple negative breast cancer previously treated with platinum-based chemotherapy. Treatments were tolerable, and the authors report a median progression-free survival of 4.0 months with olaparib and 6.1 months with olaparib plus durvalumab, both significantly longer than previously observed outcomes. Germline BRCA mutation or PD-L1 status had no observable effect on clinical benefit, yet patients who had achieved partial...
Skip Nav Destination
Article navigation
1 April 2024
Highlights|
April 01 2024
Selected Articles from This Issue
Online ISSN: 1557-3265
Print ISSN: 1078-0432
©2024 American Association for Cancer Research
2024
American Association for Cancer Research
Clin Cancer Res (2024) 30 (7): 1215.
Citation
Selected Articles from This Issue. Clin Cancer Res 1 April 2024; 30 (7): 1215. https://doi.org/10.1158/1078-0432.CCR-30-7-HI
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Pay-Per-View 24-Hour Access
$50.00
100
Views
Citing articles via
Advertisement